MORE THAN A CENTURY OF SUCCESS
1909

Dr. Josep Antoni Grífols i Roig sets up Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos in Barcelona, prior to Laboratorios Grifols. 

1940

Dr. Grífols i Roig, and his sons Josep Antoni and Víctor Grífols i Lucas, establish Laboratorios Grifols in Barcelona, a company specialized in clinical analyses and the preparation of lyophilized plasma.

1943

Production of the first single-donor lyophilized plasma in continental Europe. Grifols patents this process in Spain and develops a lyophilizer and complementary devices to later inject plasma as a therapy. 

1945

Grifols opens the first private blood bank in Spain.

1951

Dr. Josep Antoni Grífols Lucas develops the plasmapheresis technique. 

1958

First plasma fractionation plant in Spain begins operations. 

SINCE 1909 WE HAVE STRENGTHENED OUR COMMITMENT TO IMPROVING THE HEALTH AND WELL-BEING OF PEOPLE. MORE THAN 100 YEARS PROMOTING A SUSTAINABLE BUSINESS MODEL BASED ON CONTINUOUS INNOVATION AND ETHICAL LEADERSHIP
1973

Grifols opens its new production facility in Barcelona. 

1995

Dr. Víctor Grífols i Lucas lead Grifols to become the first non-U.S. company to obtain a FDA establishment license and a FDA license for a biological product (albumin). 

2002

Grifols acquires the U.S.-based company SeraCare, currently Biomat USA, along with its 43 donors centers. 

2003

Grifols acquires the assets of Alpha Therapeutic Corporation-Mitsubishi, including its plasma therapy manufacturing plant in Los Angeles, California. 

2006

FDA grants approval for immunoglobulin Barcelona plant (IVIG). 


Grifols is listed on the Spanish stock exchange.

2011

Grifols acquires Talecris Biotherapeutics to become the third-largest global manufacturer of plasma-derived protein therapies. 

Grifols is listed on the NASDAQ stock exchange.

2014

Acquisition of the transfusional diagnostic assets from Novartis.

2016

Acquisition of Hologic’s share of NAT donor screening unit.

2019

Latest findings released from the AMBAR clinical trial, which demonstrate the positive impact of the protocol in slowing down disease progression in patients with mild to moderate Alzheimer’s.

Strategic alliance with Shanghai RAAS in China